Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more
Cytokinetics Inc (CYTK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.216x
Based on the latest financial reports, Cytokinetics Inc (CYTK) has a cash flow conversion efficiency ratio of 0.216x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-142.65 Million) by net assets ($-659.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cytokinetics Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Cytokinetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cytokinetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytokinetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AXIS Capital Holdings Ltd
NYSE:AXS
|
0.106x |
|
Keyera Corp
PINK:KEYUF
|
0.105x |
|
Accor S. A.
PA:AC
|
0.051x |
|
Charles River Laboratories
NYSE:CRL
|
0.062x |
|
Powszechny Zaklad Ubezpieczen SA
PINK:PZAKY
|
0.129x |
|
Sharetronic Data Technology Co Ltd
SHE:300857
|
0.047x |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
N/A |
|
China Railway Signal & Communication Corporation Limited
PINK:CRYCY
|
0.012x |
Annual Cash Flow Conversion Efficiency for Cytokinetics Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Cytokinetics Inc from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-659.62 Million | $-510.01 Million | 0.773x | -73.56% |
| 2024-12-31 | $-135.37 Million | $-395.89 Million | 2.924x | +172.68% |
| 2023-12-31 | $-386.32 Million | $-414.33 Million | 1.073x | -61.36% |
| 2022-12-31 | $-107.90 Million | $-299.52 Million | 2.776x | +574.97% |
| 2021-12-31 | $243.86 Million | $-142.52 Million | -0.584x | -840.97% |
| 2020-12-31 | $113.38 Million | $8.94 Million | 0.079x | -99.05% |
| 2019-12-31 | $-10.94 Million | $-90.91 Million | 8.312x | +312.97% |
| 2018-12-31 | $25.93 Million | $-101.22 Million | -3.903x | -321.28% |
| 2017-12-31 | $109.84 Million | $-101.76 Million | -0.926x | -336.38% |
| 2016-12-31 | $94.36 Million | $36.98 Million | 0.392x | +450.52% |
| 2015-12-31 | $68.59 Million | $4.88 Million | 0.071x | +114.62% |
| 2014-12-31 | $92.06 Million | $-44.84 Million | -0.487x | -243.58% |
| 2013-12-31 | $54.44 Million | $-7.72 Million | -0.142x | +69.71% |
| 2012-12-31 | $71.44 Million | $-33.44 Million | -0.468x | +50.54% |
| 2011-12-31 | $48.18 Million | $-45.59 Million | -0.946x | -48.86% |
| 2010-12-31 | $70.52 Million | $-44.83 Million | -0.636x | -866.19% |
| 2009-12-31 | $101.43 Million | $8.42 Million | 0.083x | +106.73% |
| 2008-12-31 | $49.77 Million | $-61.33 Million | -1.232x | -3997.48% |
| 2007-12-31 | $99.92 Million | $-3.00 Million | -0.030x | +93.22% |
| 2006-12-31 | $106.31 Million | $-47.17 Million | -0.444x | +17.34% |
| 2005-12-31 | $73.56 Million | $-39.48 Million | -0.537x | -69.64% |
| 2004-12-31 | $107.56 Million | $-34.03 Million | -0.316x | -195.43% |
| 2003-12-31 | $-92.03 Million | $-30.51 Million | 0.332x | -9.93% |
| 2002-12-31 | $-60.59 Million | $-22.30 Million | 0.368x | -- |